- Company
- Professor Yoo discovers specific protein expression in HCC
- by Lee, Tak-Sun Mar 19, 2024 05:45am
- On the 15th, CMIC Korea, a contract research organization (CRO), announced that the results of the RENOBATE (IIT, Phase II) trial led by Professor Changhoon Yoo (Department of Oncology, Asan Medical Center) were recently published in the international academic journal, Nature Medicine (IF=82.9). This is the first time the results of a clin
- Company
- Celltrion rolls out Zymfentra in the U.S.…its 1st new drug
- by Chon, Seung-Hyun Mar 19, 2024 05:44am
- On the 18th, Celltrion announced that it had launched Zymfentra, a subcutaneous (SC) formulation of infliximab, in the United States. Zymfentra is a subcutaneous injection formulation of Celltrion's infliximab. The company received approval from the U.S. Food and Drug Administration last year for its use as a treatment for patients with u
- Company
- New CKD drug Kerendia is reimbursed in Korea
- by Son, Hyung-Min Mar 18, 2024 05:50am
- Whether the reimbursement coverage of Bayer’s Kerendia will help address the unmet needs of patients with chronic kidney disease with type 2 diabetes, is gaining attention. Until now, blood pressure medications and diabetes drugs have been used to treat chronic kidney disease, but the introduction of Kerendia has expanded the treatment opti
- Company
- NMOSD drug Enspryng can be prescribed at general hospitals
- by Eo, Yun-Ho Mar 18, 2024 05:50am
- Enspryng, a new drug for neuromyelitis optica spectrum disorder (NMOSD) is landing in general hospitals in Korea. According to industry sources, Roche Korea's Neuromyelitis Optica Spectrum Disorder (NMOSD) drug Enspryng (satralizumab) has passed the drug committees (DCs) of tertiary hospitals including Seoul National University Hospital,
- Company
- Price nego for reimb of much-petitioned Enhertu complete
- by Eo, Yun-Ho Mar 18, 2024 05:49am
- The long journey of the petitioned anticancer drug ‘Enhertu’ if finally coming to an end. According to Dailypharm’s coverage, Daiichi Sankyo and AstraZeneca Korea recently completed drug pricing negotiations with the National Health Insurance Service (NHIS) for their antibody-drug conjugate (ADC) for HER2-positive breast cancer, Enhe
- Company
- Hanmi’s Rolvedon tops KRW 73 bil in US sales
- by Son, Hyung-Min Mar 15, 2024 05:49am
- The U.S. sales of Rolvedon (Korean product name: Rolontis), a treatment for neutropenia discovered by Hanmi Pharmaceutical, surpassed KRW 70 billion last year. Assertio plans to conduct additional clinical trials and demonstrate a competitive edge. According to the reports by Assertio on the 13th, Rolvedon generated $11 million in Q4 sal
- Company
- Sam Chun Dang seeks EMA approval for its Eylea biosimilar
- by Nho, Byung Chul Mar 15, 2024 05:48am
- Sam Chun Dang Pharm announced today that its European partner has simultaneously filed for approval of both vial and prefilled syringe formulations of its Eylea biosimilar (SCD411) in Europe. The application is notable as it is the first application filed in Europe following Korea for the prefilled syringe formulation. The application w
- Company
- Yuhan’s external investments totaled KRW 85 bil last year
- by Chon, Seung-Hyun Mar 14, 2024 05:42am
- Yuhan spent a total of KRW 85 billion in external investments. By acquiring equity investments in companies across various sectors, such as biotech venture and health-functional food, Yuhan scouted for additional acquisitions to expand its business areas. According to the Financial Supervisory Service on the 12th, Yuhan made ten external inve
- Company
- Yuhan Corp and BMS will copromote Sotyktu and Zeposia
- by Nho, Byung Chul Mar 13, 2024 05:32am
- Yuhan Corp (CEO: Wook-Je Cho) announced that the company has signed a copromotion agreement with BMS Korea (Country Manager: Hye-Young Lee) for BMS’s plaque psoriasis drug ‘Sotyktu (deucravacitinib)’ and ulcerative colitis drug ‘Zeposia (ozanimod)’ on the 11th. This strategic partnership for joint sales and marketing in Korea marks
- Company
- Bosulif prescriptions now available at general hospitals
- by Eo, Yun-Ho Mar 13, 2024 05:32am
- Bosulif (bosutinib), a drug used to treat leukemia, is now available for prescription at general hospitals. According to the industry sources, Pfizer Korea’s Bosulif, a drug used to treat Chronic Myelogenous Leukemia (CML), has passed the drug committee (DC) of general hospitals, including Seoul National University Hospital, Seoul St.
